Moreover, thymocyte selection-associated high mobility group box protein (TOX), which promotes exhaustion of tumor-infiltrating CD8+ T cells within the tumor, can be used to stratify patients during anti-tumor therapy, including anti-PD-1 immunotherapy (122). The gene discussed is CD8A; the disease is neoplasm.